NCT02557074

TREg Activation in the Treatment of the PELADE (Alopecia Areata)

TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Centre Hospitalier Universitaire de Nice · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

In a prospective pilot study the investigators showed that low doses of IL2 could be beneficial for severe AA inducing a long lasting regrowth in 4 out of the 5 patients treated. The objective of this study is to compare the long term efficacy of low doses of IL2 versus placebo in a multicenter prospective randomized double blind study.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	IL2	IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
DRUG	placebo	NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment

Timeline

• Start date: 2015-12-15
• Primary completion: 2019-02-02
• Completion: 2019-12-02
• First posted: 2015-09-22
• Last updated: 2026-03-24

Locations

6 sites across 1 country: France